nach oben

Erschienen in:

01.05.2020 | Review Article

Neurological manifestations of neurofibromatosis: a review

verfasst von: Michael Bayat, Allan Bayat

Erschienen in: Neurological Sciences | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Neurofibromatosis type 1(NF1) is a dominantly inherited genetic disorder caused by a mutation in the NF1 tumor-suppressor gene. Patients are prone to develop benign and malignant tumors not only in the central and peripheral nervous system but also in other parts of the body. Apart from tumors, neurofibromatosis may also be associated with neurological symptoms and disorders such as cerebrovascular disease, epilepsy, neuropathy, and headache. This article seeks to review the different neurological manifestations of neurofibromatosis.

Hirbe AC, Gutmann DH (2014) Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 13(8):834–843. https://doi.org/10.1016/S1474-4422(14)70063-8CrossRefPubMed

Ferner RE (2007) Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol 6(4):340–351CrossRef

Ferner RE, Hughes RA, Weinman J (1996) Intellectual impairment in neurofibromatosis 1. J Neurol Sci 138(1–2):125–133CrossRef

Campian J, Gutmann DH (2017) CNS tumors in neurofibromatosis. J Clin Oncol 35(21):2378–2385. https://doi.org/10.1200/JCO.2016.71.7199CrossRefPubMedPubMedCentral

Friedman JM, Birch P (1997) An association between optic glioma and other tumours of the central nervous system in neurofibromatosis type 1. Neuropediatrics 28:131–132CrossRef

Korones DN, Padowski J, Factor BA, Constine LS (2003) Do children with optic pathway tumors have an increased frequency of other central nervous system tumors? Neuro Oncol 5(2):116–112CrossRef

Sellmer L, Farschtschi S, Marangoni M, Heran MK, Birch P, Wenzel R, Friedman JM, Mautner VF (2017) Non-optic glioma in adults and children with neurofibromatosis 1. Orphanet J Rare Dis 12(1):34. https://doi.org/10.1186/s13023-017-0588-2CrossRefPubMedPubMedCentral

Guillamo J-S, Créange A, Kalifa C, Grill J, Rodriguez D, Doz F, Barbarot S, Zerah M, Sanson M, Bastuji-Garin S, Wolkenstein P (2003) Prognostic factors of CNS tumours in neurofibromatosis 1 (NF1) a retrospective study of 104 patients. Brain 126:152–160. https://doi.org/10.1093/brain/awg016CrossRefPubMed

Rodriguez FJ, Perry A, Gutmann DH, O’Neill BP, Leonard J, Bryant S, Giannini C (2008) Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol 67(3):240–249. https://doi.org/10.1097/NEN.0b013e318165eb75CrossRefPubMedPubMedCentral

10.

Griffith JL, Morris SM, Mahdi J, Goyal MS, Hershey T, Gutmann DH (2018) Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1. Neurol: Clin Pract 8(4):283–291. https://doi.org/10.1212/CPJ.0000000000000494CrossRef

11.

Byrne A, Connor A, Lascelles K, Siddiqui A, Hargrave D, Ferner RE (2017) Clinical presentation and prognostic indicators in 100 adults and children with neurofibromatosis 1 associated non-optic pathway brain gliomas. J Neuro-Oncol 133:609–614. https://doi.org/10.1007/s11060-017-2475-zCrossRef

12.

Mahdi J, Shah AC, Sato A, Morris SM, McKinstry RC, Listernick R, Packer RJ, Fisher MJ, Gutmann DH (2017) A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1. Neurology 88(16):1584–1589. https://doi.org/10.1212/WNL.0000000000003881CrossRefPubMedPubMedCentral

13.

Rosenfeld A, Listernick R, Charrow J, Goldman S (2010) Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv Syst 26(5):663–667. https://doi.org/10.1007/s00381-009-1024-2

14.

Gutmann DH, Rasmussen SA, Wolkenstein P, MacCollin MM, Guha A, Inskip PD, North KN, Poyhonen M, Birch PH, Friedman JM (2002) Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology 59:759–761CrossRef

15.

D’Amico A, Mazio F, Ugga L, Cuocolo R, Cirillo M, Santoro C, Perrotta S, Melis D, Brunetti A (2018) Medullary unidentified bright objects in Neurofibromatosis type 1: a case series. BMC Pediatr 18(1):91. https://doi.org/10.1186/s12887-018-1067-1CrossRefPubMedPubMedCentral

16.

Dinçer A, Yener U, Özek MM (2011) Hydrocephalus in patients with neurofibromatosis type 1: MR imaging findings and the outcome of endoscopic third ventriculostomy. AJNR Am J Neuroradiol 32(4):643–646. https://doi.org/10.3174/ajnr.A2357CrossRefPubMed

17.

Roth J, Ber R, Wisoff JH, Hidalgo ET, Limbrick DD, Berger DS, Thomale UW, Schulz M, Cinalli G, Santoro C, Constantini S (2017) Endoscopic third ventriculostomy in patients with neurofibromatosis type 1: a multicenter international experience. World Neurosurg 107:623–629. https://doi.org/10.1016/j.wneu.2017.08.053CrossRefPubMed

18.

Kraut MA, Gerring JP, Cooper KL, Thompson RE, Denckla MB, Kaufmann WE (2004) Longitudinal evolution of unidentified bright objects in children with neurofibromatosis-1. Am J Med Genet A 129A(2):113–119CrossRef

19.

Lopes Ferraz Filho JR, Munis MP, Soares Souza A, Sanches RA, Goloni-Bertollo EM, Pavarino-Bertelli EC (2008) Unidentified bright objects on brain MRI in children as a diagnostic criterion for neurofibromatosis type 1. Pediatr Radiol 38(3):305–310. https://doi.org/10.1007/s00247-007-0712-xCrossRefPubMed

20.

DeBella K, Poskitt K, Szudek J, Friedman JM (2000) Use of “unidentified bright objects” on MRI for diagnosis of neurofibromatosis 1 in children. Neurology 54(8):1646–1651CrossRef

21.

Rüegger AD, Coleman L, Hansford JR, McLean N, Dabscheck G (2018) Spinal cord hyperintensities in neurofibromatosis type 1: are they the cord equivalent of unidentified bright objects in the brain? Pediatr Neurol 86:63–65. https://doi.org/10.1016/j.pediatrneurol.2018.07.005CrossRefPubMed

22.

Ghosh PS, Rothner AD, Emch TM, Friedman NR, Moodley M (2013) Cerebral vasculopathy in children with neurofibromatosis type 1. J Child Neurol 28(1):95–101. https://doi.org/10.1177/0883073812441059CrossRefPubMed

23.

Giannantoni NM, Broccolini A, Frisullo G, Pilato F, Profice P, Morosetti R, Di Lella G, Zampino G, Della MG (2015) Neurofibromatosis type 1 associated with vertebrobasilar dolichoectasia and pontine ischemic stroke. J Neuroimaging 25(3):505–506. https://doi.org/10.1111/jon.12160CrossRefPubMed

24.

Baba T, Houkin K, Kuroda S (2008) Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry 79:900–904CrossRef

25.

Hayashi K, Morofuji Y, Horie N, Izumo T (2015) A case of neurofibromatosis type 1 complicated with repeated intracerebral hemorrhage due to quasi-moyamoya disease. J Stroke Cerebrovasc Dis 24(5):e109–e113. https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.12.029CrossRefPubMed

26.

Rasmussen S, Yang Q, Friedman JM (2001) Mortality associated with neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 68(5):1110–1118. https://doi.org/10.1086/320121CrossRefPubMedPubMedCentral

27.

Rosser TL, Vezina G, Packer RJ (2005) Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology 64(3):553–555CrossRef

28.

Cairns AG, North KN (2008) Cerebrovascular dysplasia in neurofibromatosis type 1. J Neurol Neurosurg Psychiatry 79(10):1165–1170. https://doi.org/10.1136/jnnp.2007.136457CrossRefPubMed

29.

Rea D, Brandsema JF, Armstrong D, Parkin PC, deVeber G, MacGregor D, Logan WJ, Askalan R (2009) Cerebral arteriopathy in children with neurofibromatosis type 1. Pediatrics 124(3):e476–e483. https://doi.org/10.1542/peds.2009-0152CrossRefPubMed

30.

Terry AR, Jordan JT, Schwamm L, Plotkin SR (2016) Increased risk of cerebrovascular disease among patients with neurofibromatosis type 1: population-based approach. Stroke 47(1):60–65. https://doi.org/10.1161/STROKEAHA.115.011406CrossRefPubMed

31.

Créange A, Zeller J, Rostaing-Rigattieri S, Brugières P, Degos JD, Revuz J, Wolkenstein P (1999) Neurological complications of neurofibromatosis type 1 in adulthood. Brain 122(Pt 3):473–481CrossRef

32.

Clementi M, Battistella PA, Rizzi L, Boni S, Tenconi R (1996) Headache in patients with neurofibromatosis type 1. Headache 36(1):10CrossRef

33.

Pinho RS, Fusão EF, Paschoal JKSF, Caran EMM, Minett TSC, Vilanova LCP, Masruha MR (2014) Migraine is frequent in children and adolescents with neurofibromatosis type 1. Pediatr Int 56(6):865–867. https://doi.org/10.1111/ped.12375CrossRefPubMed

34.

DiMario FJ Jr, Langshur S (2000) Headaches in patients with neurofibromatosis-1. J Child Neurol 15(4):235–238CrossRef

35.

Afridi SK, Leschziner GD, Ferner RE (2015) Prevalence and clinical presentation of headache in a National Neurofibromatosis 1 Service and impact on quality of life. Am J Med Genet A 167A(10):2282–2285. https://doi.org/10.1002/ajmg.a.37186CrossRefPubMed

36.

Ferner RE, Hughes RAC, Hall SM, Upadhyaya M, Johnson MR (2004) Neurofibromatous neuropathy in neurofibromatosis 1 (NF1). J Med Genet 41:837–841. https://doi.org/10.1136/jmg.2004.021683CrossRefPubMedPubMedCentral

37.

Drouet A, Wolkenstein P, Lefaucheur J, Pinson S, Combemale P, Gherardi R, Brugieres P, Salama J, Ehre P, Decq P, Créange A (2004) Neurofibromatosis 1-associated neuropathies: a reappraisal. Brain 127:1993–2009. https://doi.org/10.1093/brain/awh234CrossRefPubMed

38.

Kulkantrakorn K, Geller TJ (1998) Seizures in neurofibromatosis 1. Pediatr Neurol 19(5):347–350CrossRef

39.

Vivarelli R, Grosso S, Calabrese F, Farnetani M, Di Bartolo R, Morgese G, Balestri P (2003) Epilepsy in neurofibromatosis 1. J Child Neurol 18(5):338–342CrossRef

40.

Hsieh HY, Fung HC, Wang CJ, Chin SC, Wu T (2011) Epileptic seizures in neurofibromatosis type 1 are related to intracranial tumors but not to neurofibromatosis bright objects. Seizure 20(8):606–611. https://doi.org/10.1016/j.seizure.2011.04.016CrossRefPubMed

41.

Ostendorf AP, Gutmann DH, Weisenberg JL (2013) Epilepsy in individuals with neurofibromatosis type 1. Epilepsia 54(10):1810–1814. https://doi.org/10.1111/epi.12348CrossRefPubMed

42.

Pecoraro A, Arehart E, Gallentine W, Radtke R, Smith E, Pizoli C, Kansagra S, Abdelnour E, McLendon R, Mikati MA (2017) Epilepsy in neurofibromatosis type 1. Epilepsy Behav 73:137–141. https://doi.org/10.1016/j.yebeh.2017.05.011CrossRefPubMed

43.

Barba C, Jacques T, Kahane P, Polster T, Isnard J, Leijten FS, Ozkara C, Tassi L, Giordano F, Castagna M, John A, Oz B, Salon C, Streichenberger N, Cross JH, Guerrini R (2013) Epilepsy surgery in neurofibromatosis type 1. Epilepsy Res 105(3):384–395. https://doi.org/10.1016/j.eplepsyres.2013.02.021CrossRefPubMed

Titel: Neurological manifestations of neurofibromatosis: a review
verfasst von: Michael Bayat
Allan Bayat
Publikationsdatum: 01.05.2020
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 10/2020
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04400-x

A new test of action verb naming: normative data from 290 Italian adults

Original Article

Appropriateness, safety, and effectiveness of “drip and ship” teleconsultation model in Southeastern Tuscany: a feasibility study

Brief Communication

Impact of COVID-19 on neurological manifestations: an overview of stroke presentation in pandemic

Zur Zeit gratis
COVID-19
COVID-19

Serum cystatin C is associated with carotid atherosclerosis in patients with acute ischemic stroke

Original Article

Post-Traumatic Stress Disorder After Traumatic Brain Injury—A Systematic Review and Meta-Analysis

Review Article

Pediatric anti-HMGCR necrotizing myopathy: diagnostic challenges and literature review

Letter to the Editor

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Ehe schützt nicht vor Demenz

25.04.2025
Demenz
Nachrichten

Eigentlich leben Verheiratete länger und gesünder. Eine aktuelle Untersuchung kommt jedoch zu dem überraschenden Schluss, dass sie eher an Demenz erkranken als nie Verheiratete, Geschiedene oder Verwitwete.

Lohnt sich die Karotis-Revaskularisation?

25.04.2025
Karotisstenose
Nachrichten

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Neuartige Antikörpertherapie bremst MS über zwei Jahre hinweg

18.04.2025
AAN-Jahrestagung 2025
Nachrichten

Eine Therapie mit dem C40-Ligand-Blocker Frexalimab kann MS-Schübe und neue MRT-Läsionen über zwei Jahre hinweg verhindern. Dafür spricht die Auswertung einer offen fortgeführten Phase-2-Studie.

Therapiestopp bei älteren MS-Kranken kann sich lohnen

17.04.2025
AAN-Jahrestagung 2025
Nachrichten

Eine Analyse aus Kanada bestätigt: Setzen ältere MS-Kranke die Behandlung mit Basistherapeutika ab, müssen sie kaum mit neuen Schüben und MRT-Auffälligkeiten rechnen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Neurological manifestations of neurofibromatosis: a review

Abstract

Weitere Artikel der Ausgabe 10/2020

A new test of action verb naming: normative data from 290 Italian adults

Appropriateness, safety, and effectiveness of “drip and ship” teleconsultation model in Southeastern Tuscany: a feasibility study

Impact of COVID-19 on neurological manifestations: an overview of stroke presentation in pandemic

Serum cystatin C is associated with carotid atherosclerosis in patients with acute ischemic stroke

Post-Traumatic Stress Disorder After Traumatic Brain Injury—A Systematic Review and Meta-Analysis

Pediatric anti-HMGCR necrotizing myopathy: diagnostic challenges and literature review

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Neu im Fachgebiet Neurologie

Ehe schützt nicht vor Demenz

Lohnt sich die Karotis-Revaskularisation?

Neuartige Antikörpertherapie bremst MS über zwei Jahre hinweg

Therapiestopp bei älteren MS-Kranken kann sich lohnen

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten